英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
37061查看　37061　在百度字典中的解释百度英翻中〔查看〕
37061查看　37061　在Google字典中的解释Google英翻中〔查看〕
37061查看　37061　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Bempedoic Acid and Cardiovascular Outcomes in Statin . . .
    The risk of death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction (the first key secondary end point) was 15% lower with bempedoic acid than with placebo, and the
  • Bempedoic Acid Reduces Major Adverse Cardiovascular Events . . .
    Tip for Patients: For patients who cannot take a statin, bempedoic acid (Nexletol) is an alternative to statin therapy for prevention of cardiovascular disease in high-risk patients without significant liver or kidney disease
  • Nexletol: Uses, Dosage, Side Effects, Warnings - Drugs. com
    Nexletol (bempedoic acid) is an oral tablet for high cholesterol that may be used to lower the risk of heart attack and heart procedures (for example stent placement or bypass surgery), in adults not taking a statin who have known heart disease or are at
  • Nexletol shows CLEAR benefit in cardiovascular outcome trial
    New data for Esperion’s cholesterol lowering daily pill Nexletol, used when statins are not working in people at risk of a heart attack, could inject some momentum into the drug’s slow rollout
  • Statin alternative lowers heart-related deaths - Harvard Health
    The cholesterol-lowering drug bempedoic acid (Nexletol) can be a good alternative for people who can't take statins A 2023 study found that compared with a placebo, bempedoic acid can lower the risk of heart attacks and related problems
  • Nexletol From Esperion - Pharmacy Times
    The FDA has approved broad new label expansions for bempedoic acid (Nexletol; Esperion Therapeutics, Inc) to reduce the risk of myocardial infarction and coronary revascularization in adults with established cardiovascular disease (CVD) or a high risk for a CVD event who are unable to use statin therapy The medication is also approved as an adjunct to diet, alone or in combination with other
  • In Brief: Cardiovascular Outcomes with Bempedoic Acid (Nexletol)
    CONCLUSION ― In one large clinical trial in statinintolerant patients who had or were at high-risk for cardiovascular disease, the oral adenosine triphosphate- citrate lyase (ACL) inhibitor bempedoic acid (Nexletol) modestly reduced the risk of a 4-component composite of major adverse cardiovascular events (MACE) compared to placebo
  • Bempedoic Acid: A Review in Cardiovascular Risk . . . - Springer
    Oral bempedoic acid (NEXLETOL ® in the USA; Nilemdo ® in the EU) and the fixed dose combination (FDC) of bempedoic acid ezetimibe (NEXLIZET ® in the USA; Nustendi ® in the EU) are approved to reduce cardiovascular (CV) risk in statin-intolerant patients who are at high risk for, or have, CV disease A first-in-class therapy, bempedoic acid inhibits the adenosine triphosphate-citrate lyase
  • In the CLEAR‑Outcomes trial, what bempedoic acid (Nexletol . . .
    The median follow-up duration was 40 6 months (3 4 years), with 95 3% of patients followed until trial end or death 3, 4 The trial definitively established that bempedoic acid reduces cardiovascular events in statin-intolerant patients, filling a critical treatment gap for this challenging population 5, 8, 7 The American College of Cardiology





中文字典-英文字典  2005-2009